Recent advances need to be highlighted in the management of both localized and metastatic prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
New early detection and molecular characterization tools are being developed to improve differentiation of their progression profiles and reduce "overdetection" and "overtreatment" of clinically "insignificant" cancers. In addition, the development of multi-parametric MR has improved the characterization of localized cancer and introduced the new concept of focal treatment. Finally, several treatments for metastatic cancer which is resistant to castration have recently increased the therapeutic armamentarium.
Barry Delongchamps N. Are you the author?
Urology Department, Cochin Hospital, 27, rue du Faubourg Saint-Jacques, 75679 Paris cedex 14, France.
Reference: Diagn Interv Imaging. 2014 Jul-Aug;95(7-8):739-42.